Alzheimer'
Conditions
Interventions
Removal of blood Abeta by apheresis 1) Devices for Abeta removal from the blood
1-1) hexadecyl alkylated cellulose beads (HDC), 1-2) dialyzers made of polysulfone (PSf) or polyethersulfone (PES) 2) blood purification period
1-3 hr 3) Protocol 3-1) Protocol A
1 session/week x 24w. One or two series. 3-2) Protocol B
1 session/week x 12w + 1/month x 9M
Sponsors
Department of Nephrology, School of Medicine, Fujita Health University
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Non diabetic MCI/mild AD patients whose Abeta deposition in the brain is confirmed by PIB/PET
Exclusion criteria
Exclusion criteria: 1) diabetic patients 2) abnormal numbers of platelets or erythrocytes 3) with complications of severe circulatory or cardiac disorders 4) past medical history of cerebrovascular disease (infarction, bleeding etc.) 5) others whom the principal investigator decides to exclude
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Change of brain A beta measured by PIB/PET from the starting point to the end of sequential treatments of blood A beta removal | — |
Secondary
| Measure | Time frame |
|---|---|
| Change of cognitive functions measured by MMSE,WMS-R, GDS, and ADAS-JCog, from the starting point to the end of sequential treatments of blood Abeta removal | — |
Countries
Japan
Contacts
Public ContactKazunori 1. Kazunori Kawaguchi 2. Midori Hasegawa
Fujita Health University 1,3. Faculty of Clinical Engineering, School of Health Sciences, 2. Department of Nephrology, School
Outcome results
None listed